Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles
Abstract The HIV-1 envelope glycoprotein trimer is poorly immunogenic because it is covered by a dense glycan shield. As a result, recombinant Env glycoproteins generally elicit inadequate antibody levels that neutralize clinically relevant, neutralization-resistant (Tier-2) HIV-1 strains. Multivale...
Guardado en:
Autores principales: | Philip J. M. Brouwer, Aleksandar Antanasijevic, Marlon de Gast, Joel D. Allen, Tom P. L. Bijl, Anila Yasmeen, Rashmi Ravichandran, Judith A. Burger, Gabriel Ozorowski, Jonathan L. Torres, Celia LaBranche, David C. Montefiori, Rajesh P. Ringe, Marit J. van Gils, John P. Moore, Per Johan Klasse, Max Crispin, Neil P. King, Andrew B. Ward, Rogier W. Sanders |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6d2ce266cff0455eb80fcc32049d700d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle
por: Philip J. M. Brouwer, et al.
Publicado: (2019) -
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.
por: Rogier W Sanders, et al.
Publicado: (2013) -
Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
por: Sunil K. Khattar, et al.
Publicado: (2015) -
Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens.
por: Emma T Crooks, et al.
Publicado: (2021) -
Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens
por: Emma T. Crooks, et al.
Publicado: (2021)